REZIRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezira, and when can generic versions of Rezira launch?
Rezira is a drug marketed by Persion and is included in one NDA.
The generic ingredient in REZIRA is hydrocodone bitartrate; pseudoephedrine hydrochloride. There are twenty-three drug master file entries for this compound. Additional details are available on the hydrocodone bitartrate; pseudoephedrine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REZIRA?
- What are the global sales for REZIRA?
- What is Average Wholesale Price for REZIRA?
Summary for REZIRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | REZIRA at DailyMed |
US Patents and Regulatory Information for REZIRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Persion | REZIRA | hydrocodone bitartrate; pseudoephedrine hydrochloride | SOLUTION;ORAL | 022442-001 | Jun 8, 2011 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

